Feasibility and Safety of Umbilical Cord Blood Transfusion in the Treatment of Neonatal Cerebral Ischemia and Anemia
Umbilical Cord Blood Mononuclear Cell Bank in Hong Kong and Treatment of Neonatal Cerebral Ischemia and Anemia - Part IV Clinical Trial
Sponsor: China Spinal Cord Injury Network
Listed as NCT03352310, this PHASE1 trial focuses on Anemia, Neonatal and Cerebral Ischemia of Newborn and remains ongoing. Sponsored by China Spinal Cord Injury Network, it has been updated 8 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jul 2018 — Jan 2021 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Dec 2017 — May 2018 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- China Spinal Cord Injury Network
- Chinese University of Hong Kong
- Mononuclear Therapeutics Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .